Human metapneumovirus (HMPV), first identified in the Netherlands in 2001, has become a significant contributor to respiratory infections worldwide. Recent data from China indicate that HMPV accounted for 6.2% of positive respiratory illness tests and 5.4% of related hospitalisations in late 2024, ...read more
This uptick has led to increased hospital visits, particularly among children under 14, prompting health authorities to improve monitoring efforts. Despite the rise in cases, experts emphasise that HMPV does not pose the same global threat as COVID-19, given its established presence and partial immunity within the population.
Human metapneumovirus (HMPV) is a respiratory virus that causes infections similar to the common cold or flu. Discovered in 2001, it belongs to the Pneumoviridae family, which also includes respiratory syncytial virus (RSV).
The virus spreads through respiratory droplets when an infected person coughs or sneezes, as well as through direct contact with contaminated surfaces. Most individuals are exposed to HMPV in early childhood and nearly all children contract the virus by age five.
Human metapneumovirus (HMPV) is a prevalent respiratory virus affecting individuals worldwide. Recent data from China indicate a significant surge in HMPV cases, particularly among children. Reports suggest that hospitals in northern China are experiencing increased admissions due to HMPV infections, leading to concerns about the virus's rapid spread. (Source - Advertiser.com.au)
In the United States, the Centers for Disease Control and Prevention (CDC) has noted an uptick in HMPV cases since November 2024. However, the CDC emphasises that these numbers remain within pre-pandemic levels and are not currently a cause for alarm. HMPV activity generally rises during the winter flu season, with most children contracting the virus by age five. (Source - New York Post)
Specific data on HMPV prevalence in the UAE is limited. A study conducted in Dubai before the COVID-19 pandemic found that viral respiratory infections accounted for 15% of all healthcare encounters among children. While the study did not provide detailed statistics on HMPV, it highlighted the significant burden of respiratory viruses in the region. (Source - Research Square)
It's important to note that HMPV is not a new virus — it was first identified in 2001 and has been circulating globally since then. So, yes, HMPV is considered as a common respiratory virus, especially in young children, the elderly and individuals with weakened immune systems.
HMPV is generally associated with mild to moderate respiratory illnesses, but it can lead to severe outcomes in vulnerable populations such as young children, the elderly and individuals with weakened immune systems.
It's important to note that while HMPV can be serious, especially for high-risk groups, it is not considered as deadly as some other respiratory viruses. Ongoing surveillance and research are essential to better understand the virus's impact and to develop effective prevention and ment strategies.
HMPV infections are primarily caused by exposure to the virus through various means.
HMPV can infect individuals of all ages; however, certain groups are at higher risk for severe illness —
Human metapneumovirus (HMPV) infections usually last between 7 to 10 days. Symptoms usually emerge 3 to 6 days after exposure to the virus, with individuals being most contagious during this symptomatic period.
In most cases, the illness is mild and resolves on its own without the need for medical intervention. However, if symptoms persist beyond 10 days or worsen—such as increased difficulty in breathing, high fever or signs of dehydration—it's important to seek medical attention promptly. Early consultation with a healthcare provider is especially important for high-risk groups to prevent potential complications.
Human metapneumovirus (HMPV) primarily targets the respiratory system, leading to a range of symptoms from mild cold-like manifestations to severe respiratory conditions.
Here's how HMPV affects the respiratory tract —
HMPV can cause symptoms similar to the common cold. To reduce the risk of infection and prevent its spread, consider the following do's and don'ts:
Detecting HMPV involves several diagnostic methods. Healthcare providers may use the following techniques —
HMPV infections typically resolve on their own within 2 to 5 days.
Treatment focuses on alleviating symptoms and supporting recovery. Here are some recommended approaches —
Currently, there is no vaccine for HMPV. Preventive measures include practicing good hand hygiene, avoiding close contact with infected individuals and disinfecting frequently touched surfaces.
By following these guidelines, most individuals can expect a full recovery from HMPV with appropriate self-care and medical support, when necessary.
In the UAE, health insurance policies are designed to cover a wide range of medical conditions, including respiratory infections like Human Metapneumovirus (HMPV). Currently, HMPV is not classified as a separate category requiring special coverage. Instead, it falls under the general provisions for communicable diseases within standard health insurance plans.
It's important to note that while standard health insurance plans cover common medical conditions, the extent of coverage can vary based on the specific policy and provider. Therefore, it's advisable to review your health insurance policy or consult with your insurance provider to understand the specifics of your coverage, especially concerning communicable diseases like HMPV.
Human Metapneumovirus (HMPV), Influenza (Flu) and COVID-19 are all respiratory viruses that share certain similarities but also have distinct differences.
Feature |
HMPV |
Flu |
COVID-19 |
---|---|---|---|
Causative Agent |
Human Metapneumovirus |
Influenza A and B viruses |
SARS-CoV-2 virus |
Symptoms |
Similar to common cold: cough, runny nose, sore throat, fever; can lead to bronchitis or pneumonia in severe cases |
Fever, cough, sore throat, muscle aches, fatigue; can lead to severe complications like pneumonia |
Wide range: fever, cough, shortness of breath, loss of taste or smell; severe cases can lead to acute respiratory distress syndrome |
Seasonality |
Peaks in winter and spring |
Peaks in winter |
Can spread year-round; initial outbreaks noted in winter |
Severity |
Generally mild; severe illness possible in infants, elderly and immunocompromised individuals |
Can be mild to severe; higher risk of complications in young children, elderly and those with underlying health conditions |
Severity ranges from mild to severe; higher mortality rate compared to HMPV and flu, especially in older adults and those with underlying conditions |
Vaccination |
No vaccine currently available |
Annual vaccines available and recommended |
Vaccines available; booster doses recommended to maintain immunity |
Treatment |
Supportive care — no specific antiviral treatment |
Antiviral medications available; supportive care |
Antiviral treatments (e.g., remdesivir); supportive care; hospitalization in severe cases |
Disclaimer:
This article is for informational purposes only and does not intend to replace professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider for any questions or concerns you may have regarding your health or a medical condition. Do not rely solely on the information provided here for medical decisions or treatment plans.
Medical Insurance | Dubai Health Insurance Cost | Health Insurance for Kids | Health Insurance Plans for Family | Dental Insurance | Individual Health Insurance | Health Insurance Abu Dhabi | Medical Insurance Sharjah | How to check Medical Insurance status with Emirates ID | Best Medical Insurance in UAE | Health Insurance for Parents | Maternity Insurance UAE